
0:00
7:00
Another incremental week for acromegaly research, led by evidence that upper-limb joint damage is nearly universal in patients and an early AI voice test for diagnosis, while rare disease industry news was dominated by deal-making (Lilly's up-to-$1.5B Calytrix buyout, argenx's Unnatural Products acquisition), a positive pivotal hepatitis delta readout from Vir, and Novo's sickle cell filing.
More episodes from "Acromegaly Update"



Don't miss an episode of “Acromegaly Update” and subscribe to it in the GetPodcast app.








